⚡ Beyond Carbapenems: The Nacubactam Revolution in complicated UTI

from Dr RR Baliga's "Got Knowledge Doc" Podkast · host MasterMedFacts LLC

🦠 The INTEGRAL-1 trial in The Lancet delivers exciting data for resistant urinary tract infections. Cefepime–nacubactam achieved both noninferiority AND superiority vs imipenem–cilastatin in complicated UTI and acute pyelonephritis. ⚡ Strong microbiological eradication, promising ESBL activity, and favorable safety profiles suggest an important future role in carbapenem-sparing strategies. #UTI #Lancet #AntimicrobialResistance #ESBL #InfectiousDiseases #MedicalPodcasts

Episode metadata supplied by the publisher feed · Published May 21, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

⚡ Beyond Carbapenems: The Nacubactam Revolution in complicated UTI

0:00 6:16

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Dr RR Baliga's "Got Knowledge Doc" Podkast?

This episode is 6 minutes long.

When was this Dr RR Baliga's "Got Knowledge Doc" Podkast episode published?

This episode was published on May 21, 2026.

Can I download this Dr RR Baliga's "Got Knowledge Doc" Podkast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!